Objectives: In preparation for a clinical trial of therapeutic agents for children with moderate-to-severe blunt traumatic brain injuries (TBIs) in emergency departments (EDs), we conducted this feasibility study to (1) determine the number and clinical characteristics of eligible children, (2) determine the timing of patient and guardian arrival to the ED, and (3) describe the heterogeneity of TBIs on computed tomography (CT) scans.
Results: We enrolled 295 eligible children at the 16 sites over 6 consecutive months. Cardiac arrest and nonsurvivable injuries were the most common characteristics that would exclude patients from a future trial. Most children arrived within 2 hours of injury, but most guardians did not arrive until 2-3 hours after the injury. There was a substantial range in types of TBIs, with subdural hemorrhages being the most common.
Conclusion:
Enrolling children with moderate-to-severe TBI into time-sensitive clinical trials will require large numbers of sites and meticulous preparation and coordination and will prove challenging to obtain informed consent given the timing of patient and guardian arrival. The Federal Exception from Informed Consent for Emergency Research will be an important consideration for enrolling these children.
T raumatic brain injury (TBI) is the leading cause of death and permanent disability from trauma in children.
1,2 Among children 0-14 years in the United States, TBI results in an estimated 2,600 deaths, 37,000 hospitalizations, and more than 500,000 emergency department (ED) visits.
3, 4 Despite the frequency of TBI, its substantial impact on the health of children, and decades of research on the topic, there are no proven effective treatments for TBI. [5] [6] [7] Many previous therapeutic trials for TBI in both children and adults have failed for several reasons, including: (1) the small number of patients with moderate-tosevere TBI available to be studied at any one center, (2) the heterogeneity of TBIs and difficulty in controlling for this heterogeneity, (3) the variability in intra-and interinstitutional approaches to the treatment of patients with TBIs, (4) the difficulty in enrolling subjects within the therapeutic window of a treatment, and (5) ethical and regulatory obstacles associated with research in emergency settings, including the difficulty in obtaining timely written informed consent. [5] [6] [7] [8] In addition, legal guardians are frequently not available in the narrow therapeutic window of potential therapies. Therefore, the Federal Exception from Informed Consent (EFIC; 21 CFR 50.24) may be necessary to study time-sensitive interventions in a clinical trial. [9] [10] [11] Preclinical work has shown that the sooner (many) therapies are delivered to patients with TBIs, the better the outcomes. There is an ongoing international multicenter pragmatic trial of tranexamic acid (TXA) for TBI in adults (CRASH III) where patients are randomized to TXA therapy within 8 hours of injury. 12, 13 In this international trial, patients who are incapable of giving consent in emergency situations are considered an exception to the general rule of informed consent per the Declaration of Helsinki. 13, 14 There have been other recent large interventional ED-based trials of progesterone for TBI in adults (ProTECT III and SyNAPSe) worth noting (and both were stopped for futility). 15, 16 In ProTECT III, study drug was administered to adult patients within a 4-hour window using EFIC. 15 There are several examples of pediatric TBI trials that failed to accrue sufficient numbers of children due to several factors such as limited numbers of eligible children at any one site, difficulties with informed consent, and arrival of subjects outside the therapeutic window of the study intervention. 5, 8 The obstacles to successful pediatric TBI trials have not been sufficiently addressed or overcome. Given the history of prior unsuccessful pediatric TBI trials, it is necessary to conduct pretrial feasibility planning work to maximize the likelihood of a successful trial. 5, 6, 8 Conducting large clinical trials in head-injured children is difficult and requires a multidisciplinary approach. 5, 17 The Pediatric Emergency Care Applied Research Network (PECARN) was established to overcome the barriers of conducting research pertaining to acutely ill and injured children during all phases of emergency care and has a history of successful completion of large multicenter clinical trials. [18] [19] [20] [21] [22] [23] [24] [25] Due to the promising preclinical and phase II studies for the use of progesterone for adult TBI, PECARN investigators were funded to conduct feasibility planning for a clinical trial of progesterone and other promising agents for TBI in children. 26 In this article we report a prospective observational feasibility study of children with moderate-to-severe TBI presenting to 16 pediatric EDs across the United States.
The goals of this study were to (1) determine the number and clinical characteristics of children with moderate-to-severe TBI at each participating site, (2) determine the timing of patient and guardian arrival to the ED to provide informed consent within the therapeutic windows of different interventions, and (3) describe the heterogeneity of TBIs on computed tomography (CT) scans.
METHODS

Study Design and Setting
We conducted a prospective observational study at 16 level I pediatric trauma center EDs in PECARN.
During the 9-month study period (July 2011-March 2012) each site collected data on all potential eligible patients for 6 consecutive months.
Population
We prospectively enrolled children up to their 18th birthdays who presented to the ED after blunt head trauma with Glasgow Coma Scale (GCS) scores of 3-12 (i.e., moderate-to-severe TBI).
Study Data Collection
We collected clinical data using a study case report form including information about patient demographics, mechanisms of injury, clinical presentation including GCS, and time of arrival of patient and legal guardian (see Data Supplement S1 study case report form, available as supporting information in the online version of this paper). All site principal investigators (PIs) and research coordinators were trained on study methods using a combination of Web-based presentations and conference calls before the start of patient enrollment.
Clinicians and research staff completed most case report forms prospectively. To minimize missed enrollment of eligible children, research staff screened daily for all patients with blunt head trauma and GCS scores of 3-12 and then identified and retrospectively enrolled eligible children who had been missed. Physicians and research coordinators also recorded time of arrival of legally authorized guardians. The purpose of recording guardian arrival time was to estimate a time window in which written informed consent could likely be obtained from a guardian in a future interventional trial. We asked site investigators to identify the best way to record the time of arrival of the legal guardian in advance of study initiation. Some sites recorded time of arrival from their trauma record and other sites used the time of arrival as recorded by social work. The site PI or research staff member obtained the information from the treating clinician or from the medical records and did not approach the parent or patient for any information. Site research coordinators entered the data into an electronic data capture system maintained at the PECARN data center at the University of Utah.
To determine the spectrum of TBIs, each site submitted cranial CT findings for each patient enrolled in the study. The study PIs (RMS, NK) reviewed radiology reports and classified and adjudicated study CT findings. For children with normal cranial CT scans, we asked site PIs to verify whether there was indeed a history of blunt head trauma; if there was no history of head trauma, these children were excluded from the database. Three children met this exclusion criterion.
Study Definitions
In this analysis we used the following study definitions:
• Best GCS score: This was the best GCS that the patient had during their ED stay;
• Moderate TBI: GCS 9-12 inclusive;
• Severe TBI: GCS 3-8 inclusive;
• Nonsurvivable injury: This was based on the clinical judgment of the ED treating physician;
• Hypotension: Documented systolic blood pressure below 90 mm Hg for patients > 10 years, < 70 mm Hg + (age in years 9 2) for patients 1-10 years, and < 70 mm Hg for patients < 1 year;
• Hypoxia: Documented oxygen saturation of <90% for at least 15 consecutive minutes;
• Potential abusive head trauma: Assault documented as the mechanism of injury in a patient < 3 years old.
Human Subjects Protection
As this was a minimal risk study, and because it was not practical to request informed consent from each patient, we requested a waiver of informed consent. There was no interaction with the patients or guardians, and the scientific validity of the study was dependent on capturing the information from the entire population of children with moderate-to-severe TBI at each participating site. We gathered information both prospectively and retrospectively (for missed patients).
Data Analysis
We prepared data summaries using SAS software (version 9.4, SAS Institute Inc.).
RESULTS
We enrolled 295 children with blunt head trauma and GCS scores of 3-12 during the study period at the 16 EDs. All eligible patients were captured. The cumulative total of all pediatric ED visits to the 16 participating EDs during the study period was approximately 483,426. Table 1 describes patient demographics and mechanisms of injury, stratified by best GCS score in the ED. Of note, most enrolled patients were boys, and motor vehicle collisions (MVCs) were the most common mechanism of injury. One-half of the patients were transferred from another hospital to the participating ED. Of note, 180 (61%) children were intubated at the time of the best GCS in the ED, making neurologic assessment difficult. In addition, 23% (67/ 295) of enrolled children received intracranial pressure (ICP) monitoring, including only one-third (59/196) of the severely injured.
We enrolled between five and 34 patients per ED over the 6-month period. Figure 1 shows the overall ED volume of each site over the 6-month study period and numbers of patients enrolled per site. The number of eligible patients was not related to overall ED volume of individual institutions. Importantly, 77 (26%) of the 295 head-injured children in our study met one or more potential exclusion criteria for a future trial of TBI therapy.
3, 6 Clinical characteristics that would make patients potentially ineligible for a future TBI trial are described in Table 2 . The most common among these were cardiac arrest requiring cardiopulmonary resuscitation prior to arrival to the ED and nonsurvivable injury determined in the ED. Age-adjusted hypotension was noted in 9% of patients, hypoxia in 4%, and potential abusive head trauma in 6% (as noted by the mechanism "assault" for children younger than 3 years). Table 3 shows the timing of arrival of the child and the legal guardian after the time of injury. This result was stratified by whether the child was transferred from another hospital to the PECARN hospital or whether the child arrived from the field to the PECARN hospital. Overall most children with TBIs arrived within 1-2 hours of their injuries; however, most parents/guardians did not arrive until 2-3 hours or later after the injury (and some guardians [n = 8; 3%] did not arrive at all). Of importance, 50% of children were transferred from another hospital and only 44% of transferred children arrived within 2-3 hours of their injuries; most of their guardians did not arrive until 4-5 hours after the injury, which has substantial implications for informed consent for time-sensitive therapies. We also examined the timing of guardian arrival based on mechanism of injury and GCS score and we found that a higher percentage of guardians arrived 3 or more hours after injury for the more severely injured children and for children involved in MVCs.
The description and distribution of TBIs on CT are provided in Table 4 . There was great heterogeneity in types of TBIs, with subdural hemorrhage being the most common intracranial injury, followed by subarachnoid hemorrhage. Of note, one-third of CT scans were normal.
DISCUSSION
In this study we documented the number of children with moderate-to-severe TBIs presenting to individual EDs in PECARN and demonstrated great variation in numbers between sites. In addition, up to onequarter of these children might be excluded from a clinical trial because they met potential exclusion criteria. When we considered only those children with severe TBIs, less than one-third subsequently had ICP monitors placed. Furthermore, we found a mismatch between the time of the patients' arrival and that of their guardians, with most patients arriving in GCS = Glasgow Coma Scale; ICP = intracranial pressure; MRI = magnetic resonance imaging; MVC = motor vehicle collision. *Forty-two subjects GCS scores improved to >12 in the ED; therefore, they are not included in columns 2 and 3.
the treating ED within 1-2 hours of their injuries and most guardians not arriving until 2-3 hours or later after the injuries. Importantly, guardians of children who were transferred from other hospitals took twice as long to arrive to the study hospitals than nontransferred children's' guardians. We also showed great heterogeneity of TBIs on CT and up to onethird of children had normal initial CT scans. Notably, we also found that the number of potential future study patients does not correlate with total ED patient volume, highlighting the differences in the types of patients seen between pediatric EDs. There was substantial variation in the numbers of patients with moderate-to-severe TBI presenting to individual pediatric trauma centers and this variation was not related to overall ED volume. This demonstrates that site selection is critical to reach adequate sample sizes in future interventional trials of TBI in children. This issue may partially account for the lack of adequate patient accrual in prior pediatric TBI trials. [5] [6] [7] [8] We collected data on controversial potential exclusion criteria for pediatric TBI trials (Table 2) . These include age-adjusted hypotension, hypoxia, and suspected abusive head trauma. Prior studies have typically excluded children with these conditions for fear of biasing the sample given that outcomes after TBI have been shown to be worse after a single episode of hypotension or hypoxia. 5, 8, 27 The patient history in children with suspected abusive head trauma may be unreliable, and it may not be possible to accurately determine the time of injury. Despite these issues, and given both the lack of any proven effective treatments for pediatric TBI and the number of children with TBIs who suffer from hypotension, hypoxia, or abusive head trauma, one may argue about the ethics of excluding these children from a future clinical trial of a promising therapeutic agent for TBI.
Published guidelines recommend ICP monitoring for the management of children with severe TBIs. 28 In this study, however, we found that less than one- 29 The relative infrequency of ICP monitoring in our study may reflect that head-injured children with low GCS scores due to intubation with pharmacologic sedation and paralysis may have been found not to have severe TBI when the sedation and paralysis were reversed; the relative infrequency of ICP monitor use may also reflect practice variation between physicians. Therefore, in future pediatric TBI clinical trials conducted in the ED it may be important to consider timely reversal of paralysis and sedation to determine the true GCS score or to accurately determine the GCS score in the prehospital setting prior to paralysis, sedation, and intubation. Future trials will also require standardization of care of these patients beyond the study intervention. The lower-than-expected number of children with severe TBI and subsequent ICP monitor placement in the current study may also reflect the number of children in the cohort who had nonsurvivable injuries identified in the ED and therefore did not have ICP monitors placed.
We found that one-half of all children with moderate-to-severe head injuries were transferred from another facility and that approximately one-half of children were present in the study ED within 2 hours of injury. The time lag between injury and arrival to the definitive treatment hospital is potentially concerning for future interventional trials given the time-sensitive nature of many TBI therapies to be tested. Of greater concern, however, is that only approximately one-half of legal guardians were present in the ED within 2-3 hours of their child's injury. Our finding that most guardians of children transferred from other hospitals took 4-5 hours to arrive and that one-half of the children in our study were transferred is concerning given the time-sensitive nature of interventions in many TBI trials. Guardian arrival time starts the window in which written informed consent could be obtained. This has important implications for future pediatric trials of therapies for TBI if these therapies have narrow windows of efficacy. In particular, delayed availability of a legal guardian argues for use of EFIC in pediatric trials of TBI therapies.
10,11 Furthermore, even in cases where the guardian is at the bedside in a timely manner, the level of stress and anxiety over the critical condition of their children may preclude guardians from providing true informed consent. PECARN is currently conducting a trial of second-line therapy in children with refractory status epilepticus CT = computed tomography. *Of the 190 with CT findings, 44 had one finding and 146 had more than one finding. †Diffuse axonal injury (3.7%), shear injury (1.6%), and traumatic infarction (1.6%), diastasis of the skull (0.5%).
using EFIC. 30 Although many of the patients' guardians are present at the bedside, the life-threatening nature of status epilepticus, the need for timely treatment, and the level of stress and anxiety among guardians makes it difficult to have a true informed consent discussion before initiating treatment. Similarly the ProTECT III trial of progesterone for TBI in adults was conducted using the EFIC. 15 The most common injury mechanisms in the study were MVCs. With this particular mechanism, many guardians may have been victims as well and taken to adult facilities for treatment. Furthermore, approximately one-half of the children in our study were transported from another hospital for definitive treatment and many ambulances do not allow guardians to travel with their children. Lack of guardian availability in the ED for children with TBIs has been demonstrated in other studies, 9 again arguing for EFIC. 10 In the CRASH I trial (which included children older than 16 years of age) sites which had to obtain written informed consent took significantly longer to randomize patients and ultimately to administer study drug (3 hours vs. 4 hours). 31, 32 Our study also showed substantial heterogeneity of intracranial injuries among children with moderate-tosevere TBIs. The implications of this may be important, as certain interventions may target specific types of intracranial injuries. For example, progesterone has been shown to have several different mechanisms of action and, therefore, adult progesterone trials have typically enrolled patients with all types of intracranial injuries that could theoretically benefit from the actions of progesterone (recent negative trials notwithstanding). 15, 16 However, future trials of targeted therapies may need to enroll children with specific injury types, such as TXA for intracranial hemorrhage. [33] [34] [35] [36] [37] In our cohort, intracranial hemorrhage was the most common type of brain injury on CT, accounting for approximately one-half of enrolled patients.
Surprisingly, even after site PI review of enrolled patients (all with moderate-to-severe TBIs) one-third of these children had normal initial CT scans. If future trials require abnormal CT scans as an inclusion criterion a substantial proportion of potentially eligible patients with initial normal CT scans may be missed. We did not evaluate, however, how many of these children had MRI or CT scans performed later, which demonstrated serious injuries not apparent on the initial CT scans. In addition, it may take some time to determine the final, definitive CT interpretation when a child presents to the ED with TBI. Therefore, waiting for the CT scan to be definitively interpreted to determine eligibility for a TBI trial could significantly delay patient enrollment and threaten administration of trial drug during the therapeutic window.
LIMITATIONS
This study had some limitations. We conducted the study using a waiver of informed consent; therefore, we did not approach parents to assess their willingness to consent to a future interventional trial for TBI. To define who would be truly eligible we would have needed to intervene and reverse paralysis and sedation for each intubated patient to evaluate who had a GCS of 3 because of pharmacologic sedation/paralysis rather than severe TBI. However, the need to obtain informed consent would bias our ability to capture all patients for the outcomes of interest. As a result, by using GCS alone we likely overestimated the available number of children for a future TBI trial. In addition, we did not follow patients to document outcomes because of the same concerns about informed consent potentially biasing the main objectives of the study. Documenting outcomes of TBI was also beyond the scope of our study, in which the aim was to quantify the number of patients eligible for a future trial and assess time of patient and guardian arrival to prepare for patient/guardian consent in future TBI trials. We were able to do this without consent and captured all patients. Outcomes of moderate-to-severe TBI in children are known and were not the focus here. In addition, although some patients were enrolled retrospectively, the limited data set was highly objective (e.g., time of patient arrival, GCS score) and this allowed us to capture all eligible patients. We also found that some sites have no standardized documentation of parental presence. Therefore, each site determined the best method for documenting this presence for their setting. This is a source of documentation that should be standardized across all pediatric trauma centers.
Future trials of TBI in children will require inclusion of many high-enrolling sites, may require international collaboration, and will likely take several years to perform. However, if such definitive studies result in demonstrating novel therapies to be effective for the treatment of moderate-to-severe TBI in children, the costs and efforts will be greatly outweighed by the reduction of morbidity and mortality and quality lifeyears saved.
CONCLUSIONS
In summary, we identified the number, timing of arrival, and important clinical and computed tomography characteristics of potentially eligible children with moderate-to-severe traumatic brain injuries for future clinical trials of novel therapeutic agents. Enrolling children with moderate-to-severe traumatic brain injuries into clinical trials is challenging and will require large numbers of sites and meticulous preparation and coordination and will prove challenging with regard to timing of patient and guardian arrival. Given these challenges, the Federal Exception from Informed Consent for Emergency Research will be an important consideration for timely enrollment of children into traumatic brain injury clinical trials.
